About I78-tfw_yef-dg_rt

This author has not yet filled in any details.
So far I78-tfw_yef-dg_rt has created 16 blog entries.

OncoTartis completed a non-GLP formal toxicology study of OT-82 on rats (21 day) and monkeys (28 days) and successfully determined a safe dose range for human clinical studies. These studies are planned to be repeated under GLP conditions starting in 1Q15.

October 30th, 2014|

Nanosyn, Inc., a Santa Clara, CA based chemistry CRO, completed process development for scaling up and manufacturing OT-82 drug candidate on a kilo scale.

May 16th, 2014|

OncoTartis expanded its research facility by adding more than 2,300 square feet of the new custom-built laboratories equipped for a regular scientific bench work, as well as for testing cultured cancer cells response to discovered anti-cancer compounds.

April 1st, 2014|

The Innovation Center started conversion of a vacant space adjacent to OncoTartis facilities into biological laboratories. Project completion is expected in March 2014.

November 19th, 2013|

OncoTartis relocates to the Innovation Center at Buffalo Niagara Medical Campus. Company’s laboratories and offices occupy 3,000 square feet at 640 Ellicott Street, Buffalo, New York.

February 27th, 2013|

OncoTartis, Inc. raised $6.4 million in a Series A financing and started its operations in Buffalo, NY.

February 17th, 2011|